case_images: PMC7649895_01
case_images: Graphical representation of the paclitaxel dose-management strategy used to allow continued ramucirumab plus paclitaxel therapy for (a) case 1, (b) case 2, (c) case 3, and (d) case 4. Case 2 was censored for initiation of a new anti-cancer therapy and subsequently died 1 month later. The calculated duration of response was based on time from the date of response until death (without documented progression).. PAC: paclitaxel; RAM: ramucirumab.
case_images: 10.1177_2050313X20970753-fig1.jpg
case_images: PMC7649895_04_10.1177_2050313X20970753-fig1.jpg
case_images: fig1-2050313X20970753
case_images: Grade 3 neutropenia in each of cycles 3, 4, and 5 (duration 7 days in each instance) led to omission of the paclitaxel dose on day 8 in each of those cycles (Figure 1(d)).
case_images: PMC7649895_02
case_images: Graphical representation of the paclitaxel dose-management strategy used to allow continued ramucirumab plus paclitaxel therapy for (a) case 1, (b) case 2, (c) case 3, and (d) case 4. Case 2 was censored for initiation of a new anti-cancer therapy and subsequently died 1 month later. The calculated duration of response was based on time from the date of response until death (without documented progression).. PAC: paclitaxel; RAM: ramucirumab.
case_images: 10.1177_2050313X20970753-fig1.jpg
case_images: PMC7649895_04_10.1177_2050313X20970753-fig1.jpg
case_images: fig1-2050313X20970753
case_images: Grade 3 neutropenia in each of cycles 3, 4, and 5 (duration 7 days in each instance) led to omission of the paclitaxel dose on day 8 in each of those cycles (Figure 1(d)).
case_images: PMC7649895_03
case_images: Graphical representation of the paclitaxel dose-management strategy used to allow continued ramucirumab plus paclitaxel therapy for (a) case 1, (b) case 2, (c) case 3, and (d) case 4. Case 2 was censored for initiation of a new anti-cancer therapy and subsequently died 1 month later. The calculated duration of response was based on time from the date of response until death (without documented progression).. PAC: paclitaxel; RAM: ramucirumab.
case_images: 10.1177_2050313X20970753-fig1.jpg
case_images: PMC7649895_04_10.1177_2050313X20970753-fig1.jpg
case_images: fig1-2050313X20970753
case_images: Grade 3 neutropenia in each of cycles 3, 4, and 5 (duration 7 days in each instance) led to omission of the paclitaxel dose on day 8 in each of those cycles (Figure 1(d)).
case_images: PMC7649895_04
case_images: Graphical representation of the paclitaxel dose-management strategy used to allow continued ramucirumab plus paclitaxel therapy for (a) case 1, (b) case 2, (c) case 3, and (d) case 4. Case 2 was censored for initiation of a new anti-cancer therapy and subsequently died 1 month later. The calculated duration of response was based on time from the date of response until death (without documented progression).. PAC: paclitaxel; RAM: ramucirumab.
case_images: 10.1177_2050313X20970753-fig1.jpg
case_images: PMC7649895_04_10.1177_2050313X20970753-fig1.jpg
case_images: fig1-2050313X20970753
case_images: Grade 3 neutropenia in each of cycles 3, 4, and 5 (duration 7 days in each instance) led to omission of the paclitaxel dose on day 8 in each of those cycles (Figure 1(d)).